Mechanisms and the clinical relevance of complex drug–drug interactions

Arthur G Roberts, Morgan E Gibbs Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA, USA Abstract: As a result of an increasing aging population, the number of individuals taking multiple medications simultaneously has grown considerably. For these individuals, taking multiple...

Full description

Saved in:
Bibliographic Details
Main Authors: Roberts AG (Author), Gibbs ME (Author)
Format: Book
Published: Dove Medical Press, 2018-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d734dc33e4c54a9585b71ba582df740f
042 |a dc 
100 1 0 |a Roberts AG  |e author 
700 1 0 |a Gibbs ME  |e author 
245 0 0 |a Mechanisms and the clinical relevance of complex drug–drug interactions 
260 |b Dove Medical Press,   |c 2018-09-01T00:00:00Z. 
500 |a 1179-1438 
520 |a Arthur G Roberts, Morgan E Gibbs Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA, USA Abstract: As a result of an increasing aging population, the number of individuals taking multiple medications simultaneously has grown considerably. For these individuals, taking multiple medications has increased the risk of undesirable drug–drug interactions (DDIs), which can cause serious and debilitating adverse drug reactions (ADRs). A comprehensive understanding of DDIs is needed to combat these deleterious outcomes. This review provides a synopsis of the pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms that underlie DDIs. PK-mediated DDIs affect all aspects of drug disposition: absorption, distribution, metabolism and excretion (ADME). In this review, the cells that play a major role in ADME and have been investigated for DDIs are discussed. Key examples of drug metabolizing enzymes and drug transporters that are involved in DDIs and found in these cells are described. The effect of inhibiting or inducing these proteins through DDIs on the PK parameters is also reviewed. Despite most DDI studies being focused on the PK effects, DDIs through PD can also lead to significant and harmful effects. Therefore, this review outlines specific examples and describes the additive, synergistic and antagonistic mechanisms of PD-mediated DDIs. The effects DDIs on the maximum PD response (Emax) and the drug dose or concentration (EDEC50) that lead to 50% of Emax are also examined. Significant gaps in our understanding of DDIs remain, so innovative and emerging approaches are critical for overcoming them. Keywords: inhibition, induction, synergism, additive, antagonism, adverse drug reactions, ADRs 
546 |a EN 
690 |a pharmacokinetics 
690 |a pharmacodynamics 
690 |a drug metabolism 
690 |a drug transporters 
690 |a ADME 
690 |a drug-drug interactions 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Clinical Pharmacology: Advances and Applications, Vol Volume 10, Pp 123-134 (2018) 
787 0 |n https://www.dovepress.com/mechanisms-and-the-clinical-relevance-of-complex-drug-drug-interaction-peer-reviewed-article-CPAA 
787 0 |n https://doaj.org/toc/1179-1438 
856 4 1 |u https://doaj.org/article/d734dc33e4c54a9585b71ba582df740f  |z Connect to this object online.